Low-toxic combination chemotherapy for limited small-cell lung cancer

Thirty-four previously untreated patients with limited small-cell lung cancer received intravenous etoposide, epirubicin, and cyclophosphamide alternated with cisplatin and etoposide, for a total of six courses, at three-week intervals, on an outpatient basis. The present induction chemotherapy regimen is an active and moderately toxic treatment for limited small-cell lung cancer